November 18, 2015
Health Canada to review Janssen’s NDS for daratumumab for Multiple Myeloma
Health Canada has accepted for review Janssen’s new drug submission (NDS) for daratumumab for treatment of Multiple Myeloma.
Pharmaceuticals, Biotechnology and Life Sciences
Health Canada has accepted for review Janssen’s new drug submission (NDS) for daratumumab for treatment of Multiple Myeloma.
The US Food and Drug Administration (FDA) has granted avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, Breakthrough…